Index RUT P/E - EPS (ttm) -1.40 Insider Own 35.39% Shs Outstand 30.85M Perf Week -6.14%
Market Cap 874.82M Forward P/E - EPS next Y -0.32 Insider Trans -0.19% Shs Float 19.97M Perf Month 23.69%
Enterprise Value 501.88M PEG - EPS next Q 0.03 Inst Own 56.09% Short Float 9.34% Perf Quarter 28.93%
Income -42.98M P/S 2.77 EPS this Y -42.88% Inst Trans 5.33% Short Ratio 6.87 Perf Half Y 35.93%
Sales 315.55M P/B 0.78 EPS next Y -214.35% ROA -3.51% Short Interest 1.87M Perf YTD 53.22%
Book/sh 36.49 P/C 2.33 EPS next 5Y - ROE -3.80% 52W High 31.04 -8.83% Perf Year 44.61%
Cash/sh 12.16 P/FCF - EPS past 3/5Y - -129.89% ROIC -3.80% 52W Low 14.57 94.23% Perf 3Y -19.56%
Dividend Est. - EV/EBITDA - Sales past 3/5Y -34.15% 54.19% Gross Margin 38.71% Volatility 3.03% 4.27% Perf 5Y -30.35%
Dividend TTM - EV/Sales 1.59 EPS Y/Y TTM 74.64% Oper. Margin -22.50% ATR (14) 1.02 Perf 10Y -
Dividend Ex-Date - Quick Ratio 7.01 Sales Y/Y TTM 13.60% Profit Margin -13.62% RSI (14) 55.93 Recom 2.00
Dividend Gr. 3/5Y - - Current Ratio 7.01 EPS Q/Q 55.38% SMA20 -1.15% Beta 0.62 Target Price 33.67
Payout - Debt/Eq 0.01 Sales Q/Q 17.18% SMA50 12.30% Rel Volume 0.59 Prev Close 28.48
Employees 1313 LT Debt/Eq 0.01 Earnings Nov 07 BMO SMA200 35.81% Avg Volume 271.45K Price 28.30
IPO Sep 29, 2016 Option/Short Yes / Yes EPS/Sales Surpr. 162.44% 3.24% Trades
Volume 160,380 Change -0.63%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-05-25 Upgrade UBS
Neutral → Buy
$30
Dec-07-23 Initiated UBS
Neutral
$35
Dec-08-22 Downgrade Piper Sandler
Overweight → Neutral
$65 → $40
Nov-18-22 Initiated Raymond James
Outperform
$45
Aug-25-22 Initiated Credit Suisse
Outperform
$65
Feb-04-22 Resumed Piper Sandler
Overweight
$80
Aug-05-21 Resumed Credit Suisse
Underperform
$55
Jan-08-21 Downgrade Credit Suisse
Neutral → Underperform
$42 → $40
Nov-24-20 Downgrade BTIG Research
Buy → Neutral
Aug-20-20 Initiated Oppenheimer
Outperform
$75
May-29-20 Initiated BTIG Research
Buy
$20
Nov-05-19 Upgrade Piper Jaffray
Neutral → Overweight
Mar-01-18 Downgrade Piper Jaffray
Overweight → Neutral
Nov-07-17 Downgrade Raymond James
Outperform → Mkt Perform
Show Previous Ratings
Nov-08-25 02:05AM
Nov-07-25 04:05PM
08:20AM
07:05AM
Nov-06-25 06:35PM
07:05AM
Loading…
Oct-21-25 07:05AM
Oct-20-25 06:00AM
Oct-16-25 07:00AM
Sep-11-25 07:00PM
Aug-02-25 03:07AM
Aug-01-25 04:26PM
08:10AM
07:00AM
Jul-17-25 07:00AM
Jul-10-25 04:05PM
08:11AM
Loading…
May-19-25 08:11AM
May-03-25 03:03AM
May-02-25 11:35PM
(Thomson Reuters StreetEvents) +19.07%
12:27PM
08:10AM
07:00AM
Apr-21-25 04:37PM
Apr-10-25 04:05PM
Apr-04-25 02:30PM
Mar-24-25 08:01AM
Mar-20-25 05:46AM
Mar-07-25 06:19PM
Feb-28-25 11:30PM
(Thomson Reuters StreetEvents)
08:10AM
07:00AM
04:05PM
Loading…
Feb-06-25 04:05PM
Dec-09-24 09:55AM
Nov-22-24 12:00PM
Nov-19-24 07:16PM
Nov-09-24 07:31AM
02:05AM
Nov-08-24 08:15AM
07:00AM
Nov-05-24 08:00AM
Nov-01-24 08:08AM
Oct-31-24 08:00AM
Oct-17-24 04:05PM
Aug-13-24 12:00PM
09:55AM
Aug-02-24 08:15AM
07:00AM
Jul-18-24 04:36AM
Jul-11-24 04:05PM
Jun-10-24 01:00AM
Jun-03-24 08:00AM
May-24-24 08:00AM
May-15-24 04:21AM
(Pharmaceutical Technology)
May-14-24 04:05PM
09:00AM
May-04-24 09:15AM
03:04AM
May-03-24 10:46PM
(Thomson Reuters StreetEvents)
11:53AM
08:34AM
08:15AM
07:00AM
Apr-11-24 04:05PM
Feb-29-24 09:31AM
Feb-28-24 10:18PM
(Thomson Reuters StreetEvents) -8.14%
07:35AM
07:00AM
Feb-13-24 08:00AM
Feb-09-24 08:31AM
Nov-25-23 09:45AM
Nov-14-23 04:30PM
Nov-05-23 09:02AM
Nov-03-23 10:26PM
(Thomson Reuters StreetEvents) +13.24%
04:05PM
08:52AM
08:45AM
07:00AM
Oct-30-23 03:46PM
Oct-25-23 08:00AM
Oct-18-23 09:44AM
Oct-17-23 08:00AM
Aug-05-23 08:56AM
Aug-04-23 10:08PM
(Thomson Reuters StreetEvents)
-12.82%
08:15AM
07:00AM
Jul-24-23 04:05PM
Jul-18-23 08:00AM
Jun-21-23 08:00PM
Jun-14-23 11:40AM
Jun-06-23 07:45AM
Jun-05-23 08:30AM
May-23-23 09:53AM
08:20AM
May-18-23 04:05PM
May-08-23 11:15AM
09:40AM
May-05-23 08:15AM
07:00AM
Apr-26-23 08:00PM
Apr-20-23 04:05PM
Apr-16-23 02:01PM
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Xie Jian President and COO Dec 02 '25 Sale 28.33 1,140 32,298 336,749 Dec 03 05:04 PM Gao Hanlin Chief Scientific Officer Dec 02 '25 Sale 28.33 1,075 30,457 952,890 Dec 03 05:04 PM Xie Jian President and COO Nov 28 '25 Sale 29.57 1,198 35,424 337,889 Dec 01 09:14 PM Gao Hanlin Chief Scientific Officer Nov 28 '25 Sale 29.57 943 27,884 953,965 Dec 01 09:14 PM Gao Hanlin Officer Dec 02 '25 Proposed Sale 28.52 1,070 30,516 Dec 01 09:13 PM Xie Jian Officer Dec 02 '25 Proposed Sale 28.52 1,135 32,370 Dec 01 09:12 PM Xie Jian Officer Nov 28 '25 Proposed Sale 30.15 1,198 36,120 Nov 26 08:26 PM Gao Hanlin Officer Nov 28 '25 Proposed Sale 30.15 943 28,431 Nov 26 08:24 PM Xie Jian President and COO Nov 24 '25 Sale 30.47 681 20,752 339,087 Nov 25 04:30 PM Gao Hanlin Chief Scientific Officer Nov 24 '25 Sale 30.47 535 16,303 954,908 Nov 25 04:30 PM Xie Jian Officer Nov 24 '25 Proposed Sale 30.47 681 20,752 Nov 24 06:37 PM Gao Hanlin Officer Nov 24 '25 Proposed Sale 30.47 535 16,303 Nov 24 06:36 PM Xie Jian President and COO Nov 19 '25 Sale 29.10 10,000 290,983 349,768 Nov 21 04:30 PM Xie Jian Officer Nov 19 '25 Proposed Sale 29.10 10,000 290,983 Nov 19 08:03 PM Gao Hanlin Chief Scientific Officer Sep 03 '25 Sale 22.03 1,063 23,414 957,085 Sep 03 05:33 PM Xie Jian President and COO Sep 03 '25 Sale 22.03 1,128 24,846 364,121 Sep 03 05:33 PM Xie Jian Officer Sep 03 '25 Proposed Sale 22.03 1,128 24,846 Sep 03 05:29 PM Gao Hanlin Officer Sep 03 '25 Proposed Sale 22.03 1,063 23,414 Sep 03 05:29 PM Xie Jian President and COO Aug 27 '25 Sale 21.48 1,199 25,760 365,249 Aug 28 06:55 PM Gao Hanlin Chief Scientific Officer Aug 27 '25 Sale 21.48 943 20,260 958,148 Aug 28 06:55 PM Xie Jian Officer Aug 27 '25 Proposed Sale 21.48 1,199 25,760 Aug 27 07:49 PM Gao Hanlin Officer Aug 27 '25 Proposed Sale 21.48 943 20,260 Aug 27 07:47 PM Xie Jian President and COO Aug 25 '25 Sale 21.50 696 14,965 366,448 Aug 26 07:13 PM Gao Hanlin Chief Scientific Officer Aug 25 '25 Sale 21.50 548 11,783 959,091 Aug 26 07:10 PM Xie Jian Officer Aug 25 '25 Proposed Sale 21.50 696 14,965 Aug 25 08:24 PM Gao Hanlin Chief Scientific Officer Jun 02 '25 Sale 20.29 754 15,299 961,281 Jun 03 04:47 PM Xie Jian President and COO Jun 02 '25 Sale 20.29 1,135 23,030 371,496 Jun 03 04:46 PM Xie Jian Officer Jun 02 '25 Proposed Sale 20.29 1,135 23,030 Jun 02 04:49 PM Xie Jian President and COO May 27 '25 Sale 20.54 1,873 38,468 372,631 May 28 04:17 PM Gao Hanlin Chief Scientific Officer May 27 '25 Sale 20.54 1,039 21,339 962,035 May 28 04:16 PM Kim Paul CFO and Treasurer Mar 05 '25 Buy 15.96 100,000 1,596,470 348,282 Mar 05 06:47 PM
